{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000030","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-06-08T10:11:32+00:00","discovered_at":"2026-06-08T10:15:00.284716+00:00","generated_at":"2026-06-08T10:15:27.022363+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Nurix receives $700M upfront from Roche to co-develop BTK degrader bexobrutideg; potential $2.3B total","bullets":["Upfront cash payment of $700 million; potential development, regulatory and sales milestones up to $2.3 billion total.","Development costs shared 40% Nurix / 60% Roche; U.S. profits and losses split equally.","Ex-U.S. royalties range from low-teens to high-teens on net sales; Roche leads commercialization outside U.S.","Expansion into immunology and neurology: Phase 2 trials planned in multiple sclerosis and chronic spontaneous urticaria.","Co-development and co-commercialization in U.S. across malignant hematology; Nurix becomes fully integrated biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000030","json":"https://secwatch.observer/filing/0001549595-26-000030.json","markdown":"https://secwatch.observer/filing/0001549595-26-000030.md","text":"https://secwatch.observer/filing/0001549595-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/0001549595-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/nrix-20260606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:15:27.022363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9702c9aa9e442fc854b8a639abe4e09406afc0ac","claim":"Nurix Therapeutics, Inc. entered into Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $700.0 million (effective 2026-06-06).","evidence_excerpt":"On June 6, 2026, Nurix Therapeutics, Inc. (\" Nurix \") entered into a License and Collaboration Agreement (the \" Collaboration Agreement \"), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, \" Roche \")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/0001549595-26-000030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"F. Hoffmann-La Roche Ltd. and Genentech, Inc."},{"label":"Value","value":"$700.0 million"},{"label":"Effective","value":"2026-06-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}